SEGRO Plc

ENXTPA:SGRO Stock Report

Market Cap: €12.6b

SEGRO Valuation

Is SGRO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SGRO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SGRO (€9.2) is trading above our estimate of fair value (€5.69)

Significantly Below Fair Value: SGRO is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SGRO?

Key metric: As SGRO is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for SGRO. This is calculated by dividing SGRO's market cap by their current revenue.
What is SGRO's PS Ratio?
PS Ratio14.2x
SalesUK£734.00m
Market CapUK£10.45b

Price to Sales Ratio vs Peers

How does SGRO's PS Ratio compare to its peers?

The above table shows the PS ratio for SGRO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.2x
ARG Argan
7.3x0.7%€1.7b
URW Unibail-Rodamco-Westfield
3.6x-5.0%€10.8b
LI Klépierre
5.1x-6.8%€8.3b
GFC Gecina
8.6x0.08%€7.0b
SGRO SEGRO
14.2x5.2%€10.4b

Price-To-Sales vs Peers: SGRO is expensive based on its Price-To-Sales Ratio (14.2x) compared to the peer average (6.2x).

Price to Sales Ratio vs Industry

How does SGRO's PS Ratio compare vs other companies in the Global Industrial REITs Industry?

1 CompanyPrice / SalesEstimated GrowthMarket Cap
SGRO 14.2xIndustry Avg. 8.4xNo. of Companies11PS048121620+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: SGRO is expensive based on its Price-To-Sales Ratio (14.2x) compared to the Global Industrial REITs industry average (8.4x).

Price to Sales Ratio vs Fair Ratio

What is SGRO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SGRO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio14.2x
Fair PS Ratio9.4x

Price-To-Sales vs Fair Ratio: SGRO is expensive based on its Price-To-Sales Ratio (14.2x) compared to the estimated Fair Price-To-Sales Ratio (9.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SGRO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€9.20
€11.78
+28.0%
8.7%€13.81€9.66n/a14
Nov ’25€10.90
€11.88
+9.0%
7.9%€13.82€10.34n/a12
Oct ’25€10.90
€11.79
+8.1%
8.1%€13.79€10.32n/a12
Sep ’25€10.90
€11.49
+5.4%
7.8%€13.49€9.96n/a17
Aug ’25€11.00
€11.59
+5.4%
7.9%€13.62€10.07n/a17
Jul ’25€11.00
€11.61
+5.5%
7.6%€13.53€10.00n/a17
Jun ’25€11.00
€11.46
+4.2%
7.7%€12.56€9.52n/a18
May ’25€11.00
€11.39
+3.5%
7.8%€12.60€9.45n/a18
Apr ’25€11.00
€11.18
+1.7%
9.1%€12.62€9.05n/a18
Mar ’25€11.00
€10.97
-0.3%
9.9%€12.49€9.05n/a18
Feb ’25€11.00
€10.69
-2.8%
12.4%€12.53€7.54n/a17
Jan ’25€11.00
€10.03
-8.8%
12.2%€12.17€7.45n/a16
Dec ’24€11.00
€9.89
-10.1%
13.7%€12.27€6.78n/a16
Nov ’24€11.00
€9.83
-10.6%
13.9%€12.06€6.66€10.9017
Oct ’24€11.00
€9.98
-9.3%
11.7%€12.11€7.41€10.9018
Sep ’24€11.00
€10.22
-7.1%
12.9%€12.20€7.06€10.9018
Aug ’24€11.10
€10.46
-5.7%
11.9%€12.25€7.09€11.0018
Jul ’24€11.10
€10.66
-4.0%
11.7%€12.33€7.60€11.0018
Jun ’24€11.30
€10.62
-6.0%
11.9%€12.90€7.49€11.0018
May ’24n/a
€10.38
0%
15.6%€12.76€5.96€11.0020
Apr ’24n/a
€10.39
0%
15.4%€12.74€5.95€11.0020
Mar ’24n/a
€10.34
0%
14.2%€12.70€5.93€11.0021
Feb ’24n/a
€10.63
0%
18.2%€15.80€5.96€11.0021
Jan ’24n/a
€10.76
0%
19.7%€16.14€6.08€11.0021
Dec ’23n/a
€10.82
0%
19.6%€16.16€6.09€11.0021
Nov ’23n/a
€11.17
0%
22.5%€16.28€6.08€11.0020

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Healthcare Activos Yield SOCIMI

€245.6m

Operates as a real estate investment vehicle that focuses on the healthcare sector in Europe.

MLHAY

€1.41

7D

0%

1Y

4.4%

Paref

€60.9m

Owns and manages business real estate located primarily in the Paris region.

PAR

€40.40

7D

1.0%

1Y

-15.5%

Faifey Invest Socimi

€98.7m

Invests in real estate assets in Spain.

MLECE

€19.50

7D

0%

1Y

20.4%